Poudel Bharat, Rosenson Robert S, Kent Shia T, Bittner Vera, Gutiérrez Orlando M, Anderson Amanda H, Woodward Mark, Jackson Elizabeth A, Monda Keri L, Bajaj Archna, Huang Lei, Kansal Mayank, Rahman Mahboob, He Jiang, Muntner Paul, Colantonio Lisandro D
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama.
Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York.
Kidney Med. 2023 May 5;5(7):100648. doi: 10.1016/j.xkme.2023.100648. eCollection 2023 Jul.
RATIONALE & OBJECTIVE: Many adults with chronic kidney disease (CKD) and atherosclerotic cardiovascular disease (ASCVD) have high lipoprotein(a) levels. It is unclear whether high lipoprotein(a) levels confer an increased risk for recurrent ASCVD events in this population. We estimated the risk for recurrent ASCVD events associated with lipoprotein(a) in adults with CKD and prevalent ASCVD.
Observational cohort study.
SETTING & PARTICIPANTS: We included 1,439 adults with CKD and prevalent ASCVD not on dialysis enrolled in the Chronic Renal Insufficiency Cohort study between 2003 and 2008.
Baseline lipoprotein(a) mass concentration, measured using a latex-enhanced immunoturbidimetric assay.
Recurrent ASCVD events (primary outcome), kidney failure, and death (exploratory outcomes) through 2019.
We used Cox proportional-hazards regression models to estimate adjusted HR (aHRs) and 95% CIs.
Among participants included in the current analysis (mean age 61.6 years, median lipoprotein(a) 29.4 mg/dL [25th-75th percentiles 9.9-70.9 mg/dL]), 641 had a recurrent ASCVD event, 510 developed kidney failure, and 845 died over a median follow-up of 6.6 years. The aHR for ASCVD events associated with 1 standard deviation (SD) higher log-transformed lipoprotein(a) was 1.04 (95% CI, 0.95-1.15). In subgroup analyses, 1 SD higher log-lipoprotein(a) was associated with an increased risk for ASCVD events in participants without diabetes (aHR, 1.23; 95% CI, 1.02-1.48), but there was no evidence of an association among those with diabetes (aHR, 0.99; 95% CI, 0.88-1.10, comparing aHRs = 0.031). The aHR associated with 1 SD higher log-lipoprotein(a) in the overall study population was 1.16 (95% CI, 1.04-1.28) for kidney failure and 1.02 (95% CI, 0.94-1.11) for death.
Lipoprotein(a) was not available in molar concentration.
Lipoprotein(a) was not associated with the risk for recurrent ASCVD events in adults with CKD, although it was associated with a risk for kidney failure.
许多患有慢性肾脏病(CKD)和动脉粥样硬化性心血管疾病(ASCVD)的成年人脂蛋白(a)水平较高。目前尚不清楚高脂蛋白(a)水平是否会增加该人群复发性ASCVD事件的风险。我们评估了患有CKD和已患ASCVD的成年人中脂蛋白(a)与复发性ASCVD事件的相关性。
观察性队列研究。
我们纳入了1439例2003年至2008年期间参加慢性肾功能不全队列研究的未接受透析的CKD和已患ASCVD的成年人。
使用乳胶增强免疫比浊法测量的基线脂蛋白(a)质量浓度。
至2019年的复发性ASCVD事件(主要结局)、肾衰竭和死亡(探索性结局)。
我们使用Cox比例风险回归模型来估计校正后的风险比(aHRs)和95%置信区间(CIs)。
在当前分析纳入的参与者中(平均年龄61.6岁,脂蛋白(a)中位数为29.4mg/dL [第25-75百分位数为9.9-70.9mg/dL]),在中位随访6.6年期间,641例发生了复发性ASCVD事件,510例出现肾衰竭,845例死亡。与经对数转换的脂蛋白(a)每升高1个标准差(SD)相关的ASCVD事件的aHR为1.04(95%CI,0.95-1.15)。在亚组分析中,经对数转换的脂蛋白(a)每升高1个SD与无糖尿病参与者的ASCVD事件风险增加相关(aHR,1.23;95%CI,1.02-1.48),但在糖尿病患者中未发现相关性(aHR,0.99;95%CI,0.88-1.10,比较aHRs = 0.031)。在整个研究人群中,与经对数转换的脂蛋白(a)每升高1个SD相关的肾衰竭的aHR为1.16(95%CI,1.04-1.28),死亡的aHR为1.02(95%CI,0.94-1.11)。
无法获得脂蛋白(a)的摩尔浓度。
脂蛋白(a)与CKD成年人复发性ASCVD事件的风险无关,尽管它与肾衰竭风险相关。